![N-[(1,1-Dimethylethoxy)carbonyl]-L-leucyl-L-leucine](/upload/1124/V68255.png)
| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
Boc-Leu-Leu-OH does not possess a specific biological target; its primary function is as a chemical building block for peptide synthesis. The Boc group safeguards the amino terminus during chemical reactions, allowing for selective deprotection under acidic conditions. Its structure, consisting of two leucine residues, plays a crucial role in studying protein interactions and enzyme activities.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
This compound is not a biological agent and does not exhibit direct in vitro biological activity. Its value lies in its chemical utility as a protected dipeptide building block. It has been used in the synthesis of a peptide-based curcumin derivative with anticancer activity in vitro. It has also been used in the synthesis of fluorescent peptides containing naphthalene and protoporphyrin IX. |
| ln Vivo |
Boc-Leu-Leu-OH is not administered in vivo as a therapeutic agent. It is a research chemical utilized as a building block in peptide synthesis. The final deprotected peptide product, not this protected intermediate, would be the subject of in vivo pharmacological testing.
|
| Enzyme Assay |
Non-cellular enzyme/receptor binding assays are not applicable to Boc-Leu-Leu-OH. Its use is exclusively in organic synthesis and peptide chemistry, where it serves as a building block for creating complex peptide structures.
|
| Cell Assay |
Boc-Leu-Leu-OH is not used in cell-based assays as a therapeutic agent. Its applications are in synthetic chemistry. It is typically stored as a crystalline solid at -20°C. It is soluble in DMF (30 mg/ml), DMSO (10 mg/ml), and ethanol (30 mg/ml).
|
| Animal Protocol |
In vivo animal experiments do not involve Boc-Leu-Leu-OH as a test article. It is a chemical intermediate used in the synthesis of peptide-based drug candidates. The Boc-protected dipeptide itself is not administered to animals.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not applicable to Boc-Leu-Leu-OH as it is not a drug. It is a small molecule (MW 344.45 g/mol) with the formula C17H32N2O5. The Boc protecting group is acid-labile and designed for synthetic utility.
|
| Toxicity/Toxicokinetics |
The toxicity of Boc-Leu-Leu-OH is not extensively documented. Standard laboratory safety precautions should be followed when handling this compound, including working in a well-ventilated area with appropriate personal protective equipment.
|
| References | |
| Additional Infomation |
Boc-Leu-Leu-OH is a Boc-protected dipeptide composed of two L-leucine residues. It is widely utilized in research focused on peptide synthesis, particularly in solid-phase peptide synthesis, allowing researchers to create complex peptide structures efficiently.
|
| Molecular Formula |
C17H32N2O5
|
|---|---|
| Molecular Weight |
344.45
|
| Exact Mass |
344.231
|
| CAS # |
73401-65-7
|
| PubChem CID |
7019882
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.586
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
24
|
| Complexity |
441
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC(C[C@H](NC(OC(C)(C)C)=O)C(N[C@H](C(O)=O)CC(C)C)=O)C
|
| InChi Key |
PBTNVAYSJPRTLQ-STQMWFEESA-N
|
| InChi Code |
InChI=1S/C17H32N2O5/c1-10(2)8-12(19-16(23)24-17(5,6)7)14(20)18-13(15(21)22)9-11(3)4/h10-13H,8-9H2,1-7H3,(H,18,20)(H,19,23)(H,21,22)/t12-,13-/m0/s1
|
| Chemical Name |
(2S)-4-methyl-2-[[(2S)-4-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoyl]amino]pentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (290.32 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9032 mL | 14.5159 mL | 29.0318 mL | |
| 5 mM | 0.5806 mL | 2.9032 mL | 5.8064 mL | |
| 10 mM | 0.2903 mL | 1.4516 mL | 2.9032 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
